文献速递冠心病

依维莫司洗脱支架PCI与CABG治疗多支冠脉病变:BEST试验延长随访

Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial.
PubMed 文献 · Circulation · 2022-09-19

BEST试验为前瞻性多中心随机对照研究,原计划纳入1776例多支冠脉病变患者,因入组缓慢提前终止,实际纳入880例(PCI组438例,CABG组442例)。中位随访11.8年显示,PCI组与CABG组主要复合终点(死亡、心梗或靶血管血运重建)发生率无显著差异(34.5% vs 30.3%,HR 1.18,P=0.26),但PCI组自发性心肌梗死和再次血运重建更常见。

要点

  • 多支冠脉病变患者延长随访中,PCI与CABG的主要复合终点及全因死亡无显著差异。
  • PCI组自发性心肌梗死(HR 1.86)和再次血运重建(HR 1.92)风险显著高于CABG。
  • 研究因入组缓慢提前终止,实际样本量880例,需注意解读的局限性。

核心结论

  • 在多支冠脉病变患者中,延长随访期间PCI与CABG的主要不良心脏事件、安全复合终点及全因死亡率无显著差异。

研究设计与样本

  • 前瞻性、多中心、随机对照试验,在27个国际心脏中心开展,计划随机分配1776例造影确诊的多支冠脉病变患者。
  • 因入组缓慢提前终止,实际纳入880例患者(PCI组438例,CABG组442例),入组时间为2008年7月至2013年9月。

主要发现

  • 中位随访11.8年(四分位距10.6-12.5年,最长13.7年),主要终点(全因死亡、心肌梗死或靶血管血运重建)PCI组151例(34.5%),CABG组134例(30.3%)(HR 1.18,95%CI 0.88-1.56,P=0.26)。
  • 安全复合终点(死亡、心肌梗死或卒中)发生率PCI组28.8%,CABG组27.1%(HR 1.07,95%CI 0.75-1.53,P=0.70)。
  • 全因死亡发生率PCI组20.5%,CABG组19.9%(HR 1.04,95%CI 0.65-1.67,P=0.86)。
  • 自发性心肌梗死发生率PCI组7.1%,CABG组3.8%(HR 1.86,95%CI 1.06-3.27,P=0.031)。
  • 任何再次血运重建发生率PCI组22.6%,CABG组12.7%(HR 1.92,95%CI 1.58-2.32,P<0.001)。

临床怎么用

  • 对于多支冠脉病变患者,PCI与CABG在长期硬终点上无显著差异,但PCI与更高的自发性心肌梗死和再次血运重建风险相关,临床决策需结合患者个体情况权衡。

局限性

  • 研究因入组缓慢提前终止,实际样本量仅880例,可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term comparative outcomes after percutaneous coronary intervention (PCI) with everolimus-eluting stents and coronary artery bypass grafting (CABG) are limited in patients with multivessel coronary artery disease. METHODS: This prospective, multicenter, randomized controlled trial was conducted in 27 international heart centers and was designed to randomly assign 1776 patients with angiographic multivessel coronary artery disease to receive PCI with everolimus-eluting stents or CABG. After inclusion of 880 patients (438 in the PCI group and 442 in the CABG group) between July 2008 and September 2013, the study was terminated early because of slow enrollment. The primary end point was the composite of death from any cause, myocardial infarction, or target vessel revascularization. RESULTS: During a median follow-up of 11.8 years (interquartile range, 10.6-12.5 years; maximum, 13.7 years), the primary end point occurred in 151 patients (34.5%) in the PCI group and 134 patients (30.3%) in the CABG group (hazard ratio [HR], 1.18 [95% CI, 0.88-1.56]; P=0.26). No significant differences were seen in the occurrence of a safety composite of death, myocardial infarction, or stroke between groups (28.8% and 27.1%; HR, 1.07 [95% CI, 0.75-1.53]; P=0.70), as well as the occurrence of death from any cause (20.5% and 19.9%; HR, 1.04 [95% CI, 0.65-1.67]; P=0.86). However, spontaneous myocardial infarction (7.1% and 3.8%; HR, 1.86 [95% CI, 1.06-3.27]; P=0.031) and any repeat revascularization (22.6% and 12.7%; HR, 1.92 [95% CI, 1.58-2.32]; P<0.001) were more frequent after PCI than after CABG. CONCLUSIONS: In patients with multivessel coronary artery disease, there were no significant differences between PCI and CABG in the incidence of major adverse cardiac events, the safety composite end point, and all-cause mortality during the extended follow-up. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifiers: NCT05125367 and NCT00997828.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ahn JM, Kang DY, Yun SC, et al. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial. Circulation. 2022. PMID: 36121700. doi:10.1161/CIRCULATIONAHA.122.062188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。